Proteomics on Parade

Wednesday, November 8, 2000
By Staff ,
Washington Techway

URL: http://www.washtech.com/news/biotech/5024-1.html

That was the view at the 2000 Bioscience Forum, a two-day look at the emerging "post-genomic era" of new diagnostics and therapies in Maryland. Proteomics is the cataloging and analysis of the body's proteins.

"Proteins tell the real story of health and disease," said Sandra Steiner, vice president of proteomics applications at Large Scale Proteomics in Rockville. "It's the ultimate regulator of cell function."

It's an increasingly crowded field. Celera Genomics Group, a primary force in the sequencing of the human genome, is building a protein research facility at its Rockville headquarters.

And it's one emergence set to make biotech "this century's most dynamic industry," according to a new Ernst & Young report. Industry innovation and convergence spurred a remarkable turnaround: For the year ending June 30, 2000, the biotech industry's market capitalization was $353 billion, a 156 percent increase from a year earlier.

This article appears in the Nov. 13 issue of Washington Techway.

Category: 54. Proteomics